Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The major capsid protein L1 of Human papillomavirus type 16 (HPV16) is the primary structural component of the viral outer shell, which self-assembles into icosahedral capsids composed of 72 pentamers. This protein plays a critical role in the viral life cycle by binding to heparan sulfate proteoglycans on the surface of host basal layer keratinocytes, initiating viral attachment and subsequent endocytosis into host cells. HPV16 is a high-risk oncogenic virus strongly associated with the development of cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers. The L1 protein is the primary target for prophylactic HPV vaccines, such as Gardasil, Gardasil 9, and Cervarix, which utilize recombinant L1-based virus-like particles (VLPs) to elicit high titers of neutralizing antibodies. These antibodies block viral entry and prevent infection, although these vaccines do not exhibit therapeutic efficacy against pre-existing HPV infections.
Active immunization via recombinant virus-like particles (VLPs) to induce high titers of neutralizing antibodies that block viral attachment and entry into host cells.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major capsid protein L1 (Human papillomavirus type 16) (HPV16 L1).